IL10 and non-small cell lung carcinoma: Notably, a transient spike in IL-10 in one NSCLC patient did not correlate with immune-related adverse events (irAEs), suggesting that IL-10 fluctuations may reflect regulatory feedback rather than toxicity alone [54].